Search Results

You are looking at 1 - 10 of 224 items for :

  • "induction chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Athanassios Argiris

: 323 – 329 . 6 Argiris A Jayaram P Pichardo D . Revisiting induction chemotherapy for head and neck cancer . Oncology 2005 , 19 ( in press ). 7 Hitt R Lopez-Pousa A Rodriguez M . Phase III study comparing cisplatin (P) & 5

Full access

Nathan J. Moore, Megan Othus, Anna B. Halpern, Nicholas P. Howard, Linyi Tang, Kyle E. Bastys, Mary-Elizabeth M. Percival, Paul C. Hendrie, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, and Roland B. Walter

Background Adults with acute myeloid leukemia (AML) or other high-grade myeloid neoplasms typically remain hospitalized during the several weeks of profound pancytopenia after intensive induction chemotherapy. However, the need for

Full access

Francis P. Worden and Huan Ha

irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer . N Engl J Med 1998 ; 338 : 1798 – 1804 . 42. Adelstein DJ . Induction chemotherapy in head and neck cancer . Hematol Oncol Clin North Am 1999 ; 13

Full access

Pelin Cinar and Andrew H. Ko

dissemination during induction chemotherapy. A qualitative systematic review published in 2009 noted that, although the superiority of chemoradiation to chemotherapy alone remains unproven, this paradigm of induction chemotherapy followed by chemoradiation is a

Full access

Ahmed Abdalla, Amr Aref, Amer Alame, Mohamad Barawi, Danny Ma, and Zyad Kafri

Background: The National Comprehensive Cancer Network (NCCN) Guidelines recently recognized total neoadjuvant therapy (TNT) as an acceptable option in patients with T3 and any N rectal cancer. Previous studies suggested that patients who received chemotherapy prior to conventional preoperative chemoradiation (CRT) and surgery allowed patients to receive more of their planned treatment with a better toxicity profile and increase in pathological response. However, those studies used a long course of FOLFOX or used capecitabine and oxaliplatin as an induction regimen. We are conducting a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+. Patients and Methods: Patients with T2-T3/N0-N+ enrolled on our phase 2 prospective trial were included for this analysis. Patients received 6 cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin), which was administered every 2 weeks. After 3 weeks of recovery period, patients then received conventional CRT with 5FU or capecitabine. All patients got MRI and endorectal ultrasound (ERUS) at baseline, after completing FOLFOX 3-months regimen and after finishing conventional CRT. Patients underwent either full-thickness local excision or total mesorectal resection depending on their tumor response to neoadjuvant therapy. The time interval between completion of radiation therapy and surgery ranged between 7and 12 weeks. Results: A total of 10 patients completed the chemotherapy and CRT treatment regimen. 9 patients proceeded to surgery and the 10th patient is scheduled for surgery. Clinical downstaging by MRI or ERUS was shown in 9 of 10 patients with only 6 cycles of FOLFOX. Complete clinical response was achieved in 6 patients as evident by ERUS/MRI of the pelvis after 3 months of FOLFOX before CRT. Complete pathological response was found in 4 of 9 patients (44%). In addition, 4 other patients had significant albeit not complete pathological response. Conclusions: This study suggests that adding only 6 cycles of neoadjuvant FOLFOX before CRT improved clinical and pathological downstaging of T2-T3/N0-N+ rectal adenocarcinoma and may facilitate organ preservation surgery. This is strategy needs to be investigated in larger phase III trials to validate these findings.

Full access

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

) lung cancer: the Sloan-Kettering experience with 136 patients . Ann Thorac Surg 1993 ; 55 : 1365 – 1373 ; discussion 1373–1374 . 12. Ng KK Kris MG Ginsberg RJ . Induction chemotherapy employing dose-intense cisplatin with mitomycin and

Full access

Daniel A. Pollyea

-dose cytarabine and 3 on an anthracycline), the upfront treatment approach to AML has been decidedly binary. “We judged a patient's ‘fitness’ for induction chemotherapy, and if that was an available option, that is what they received,” said Dr. Pollyea. “If it

Full access

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

induction chemotherapy, CRT followed by surgical resection, or definitive CRT without surgery. The decision-making between these options is carefully reviewed in this paper, but the one constant in all treatment decisions is the need for systemic therapy

Full access

Gordon Taylor Moffat, Tao Wang, and Andrew G. Robinson

strategies. In our patient, chemotherapy followed by a targeted inhibitor was chosen due to the presence of the ALK rearrangement, as well as a somewhat discordant response to induction chemotherapy, suggesting possible progression of the ALK inhibitor

Full access

Clayton A. Smith and Lisa A. Kachnic

recommended total duration of perioperative therapy for patients with LARC is 6 months. Induction Chemotherapy and ChemoRT Most patients with LARC will receive neoadjuvant chemoRT or short-course RT followed by surgical resection and adjuvant